SenesTech Reports 88% Reduction in Rat Activity in Chicago Pilot, Building on Record $1.1 Million Quarterly Revenue Milestone
SenesTech reported an 88% reduction in rat activity in a Chicago pilot using its Evolve® Rat Birth Control™. The company also announced record Q3 2026 revenue of $1.1 million, up 40% sequentially and 55% year-over-year. Evolve is now deployed in six Chicago areas, targeting reproduction to reduce rodent populations sustainably.
How this was made
The 30-second read
Why it matters
The disclosed pilot demonstrates product efficacy and revenue growth, which could attract additional municipal contracts.
Market read
First‑time disclosure of a successful pilot and revenue milestone; modest relevance for traders tracking micro‑cap biotech/tech‑service stocks.
What to watch
Potential regulatory hurdles for widespread deployment and competition from traditional rodenticides.
Background
SenesTech is a micro‑cap NASDAQ‑listed company focused on rodent birth‑control products.
Ticker impact
SenesTech disclosed an 88% reduction in rat activity from its Chicago pilot and reported Q3 revenue of $1.1 million, a new operational milestone.
likely upward pressure as market prices in the pilot success and revenue growth.
The pilot is the first public disclosure of efficacy and revenue growth, suggesting future contract wins.
Market effects
May highlight growth potential for pest‑control and sustainable agriculture niche.
Limited to Chicago municipal contracts; modest effect on local service providers.
Low; niche market with minimal broader market impact.
Counterpoint
Pilot results may not scale; investors could remain skeptical until larger contracts are secured.
Key entities
- CompanySenesTech, Inc.
NASDAQ‑listed provider of rodent birth‑control solutions.
